Literature DB >> 30972976

Applications of molecular engineering in T-cell-based immunotherapies.

David A McBride1,2,3, Matthew D Kerr1,2,3, Shinya L Wai1,3, Nisarg J Shah1,2,3,4,5.   

Abstract

Harnessing an individual's immune cells to mediate antitumor and antiviral responses is a life-saving option for some patients with otherwise intractable forms of cancer and infectious disease. In particular, T-cell-based engineered immune cells are a powerful new class of therapeutics with remarkable efficacy. Clinical experience has helped to define some of the major challenges for reliable, safe, and effective deployment of T-cells against a broad range of diseases. While poised to revolutionize immunotherapy, scalable manufacturing, safety, specificity, and the development of resistance are potential roadblocks in their widespread usage. The development of molecular engineering tools to allow for the direct or indirect engineering of T-cells to enable one to troubleshoot delivery issues, amplify immunomodulatory effects, integrate the synergistic effects of different molecules, and home to the target cells in vivo. In this review, we will analyze thus-far developed cell- and material-based tools for enhancing T-cell therapies, including methods to improve safety and specificity, enhancing efficacy, and overcoming limitations in scalable manufacturing. We summarize the potential of T-cells as immune modulating therapies and the potential future directions for enabling their adoption for a broad range of diseases. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Cells at the Nanoscale.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  T-cells; adoptive cell transfer; cell engineering; immunotherapy

Mesh:

Substances:

Year:  2019        PMID: 30972976      PMCID: PMC7869905          DOI: 10.1002/wnan.1557

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  162 in total

1.  Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.

Authors:  Leah Alabanza; Melissa Pegues; Claudia Geldres; Victoria Shi; Jed J W Wiltzius; Stuart A Sievers; Shicheng Yang; James N Kochenderfer
Journal:  Mol Ther       Date:  2017-07-27       Impact factor: 11.454

2.  Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.

Authors:  Alena Gros; Maria R Parkhurst; Eric Tran; Anna Pasetto; Paul F Robbins; Sadia Ilyas; Todd D Prickett; Jared J Gartner; Jessica S Crystal; Ilana M Roberts; Kasia Trebska-McGowan; John R Wunderlich; James C Yang; Steven A Rosenberg
Journal:  Nat Med       Date:  2016-02-22       Impact factor: 53.440

3.  Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity.

Authors:  Takuya Maeda; Seiji Nagano; Hiroshi Ichise; Keisuke Kataoka; Daisuke Yamada; Seishi Ogawa; Haruhiko Koseki; Toshio Kitawaki; Norimitsu Kadowaki; Akifumi Takaori-Kondo; Kyoko Masuda; Hiroshi Kawamoto
Journal:  Cancer Res       Date:  2016-11-21       Impact factor: 12.701

4.  Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.

Authors:  Jun Ishihara; Kazuto Fukunaga; Ako Ishihara; Hans M Larsson; Lambert Potin; Peyman Hosseinchi; Gabriele Galliverti; Melody A Swartz; Jeffrey A Hubbell
Journal:  Sci Transl Med       Date:  2017-11-08       Impact factor: 17.956

5.  Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

Authors:  Sarita M Fernandez-Poma; Diego Salas-Benito; Teresa Lozano; Noelia Casares; Jose-Ignacio Riezu-Boj; Uxua Mancheño; Edurne Elizalde; Diego Alignani; Natalia Zubeldia; Itziar Otano; Enrique Conde; Pablo Sarobe; Juan Jose Lasarte; Sandra Hervas-Stubbs
Journal:  Cancer Res       Date:  2017-05-18       Impact factor: 12.701

6.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

7.  A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.

Authors:  Jennifer D Stone; Daniel T Harris; Carolina M Soto; Adam S Chervin; David H Aggen; Edward J Roy; David M Kranz
Journal:  Cancer Immunol Immunother       Date:  2014-08-01       Impact factor: 6.968

8.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

9.  Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.

Authors:  Marie-Andrée Forget; Shruti Malu; Hui Liu; Christopher Toth; Sourindra Maiti; Charuta Kale; Cara Haymaker; Chantale Bernatchez; Helen Huls; Ena Wang; Francesco M Marincola; Patrick Hwu; Laurence J N Cooper; Laszlo G Radvanyi
Journal:  J Immunother       Date:  2014 Nov-Dec       Impact factor: 4.456

10.  Domain-swapped T cell receptors improve the safety of TCR gene therapy.

Authors:  Michael T Bethune; Marvin H Gee; Mario Bunse; Mark S Lee; Eric H Gschweng; Meghana S Pagadala; Jing Zhou; Donghui Cheng; James R Heath; Donald B Kohn; Michael S Kuhns; Wolfgang Uckert; David Baltimore
Journal:  Elife       Date:  2016-11-08       Impact factor: 8.140

View more
  2 in total

Review 1.  Cancer microenvironment and genomics: evolution in process.

Authors:  Stanley P Leong; Isaac P Witz; Orit Sagi-Assif; Sivan Izraely; Jonathan Sleeman; Brian Piening; Bernard A Fox; Carlo B Bifulco; Rachel Martini; Lisa Newman; Melissa Davis; Lauren M Sanders; David Haussler; Olena M Vaske; Marlys Witte
Journal:  Clin Exp Metastasis       Date:  2021-05-10       Impact factor: 5.150

2.  Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy.

Authors:  Sasan Ghaffari; Monireh Torabi-Rahvar; Sajjad Aghayan; Zahra Jabbarpour; Kobra Moradzadeh; Azadeh Omidkhoda; Naser Ahmadbeigi
Journal:  BMC Immunol       Date:  2021-07-03       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.